Figure 1. Quinotrierixin suppresses human retinal pigment epithelium cell proliferation. ARPE-19 cells were treated with quinotrierixin (QT), and cell proliferation was determined using 3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay (n=5; A), cell counting (n=3; B), or CyQUANT NF Cell Proliferation Assay (n=4, C). Quinotrierixin concentration was 0.5 μM unless otherwise indicated. Treatment time was 24 h for panels A and B and was 16 h for panel C. Data are expressed as mean±SD **p<0.01 versus control, ††p<0.01 versus quinotrierixin 0.1 μM.